465 related articles for article (PubMed ID: 31674740)
21. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.
Saunte DML; Jemec GBE
JAMA; 2017 Nov; 318(20):2019-2032. PubMed ID: 29183082
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
Moyano B; Clemente A; Marín-Jiménez I; Martorell A
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.
van Straalen KR; Tzellos T; Guillem P; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Jemec GBE; Katoulis AC; Koenig A; Lazaridou E; Marzano AV; Matusiak Ł; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Romaní J; Saunte DM; Skroza N; Stergianou D; Szepietowski J; Trigoni A; Vilarrasa E; van der Zee HH
J Am Acad Dermatol; 2021 Aug; 85(2):369-378. PubMed ID: 33484766
[TBL] [Abstract][Full Text] [Related]
24. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
Tchernev G
Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
[TBL] [Abstract][Full Text] [Related]
25. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.
Alikhan A; Sayed C; Alavi A; Alhusayen R; Brassard A; Burkhart C; Crowell K; Eisen DB; Gottlieb AB; Hamzavi I; Hazen PG; Jaleel T; Kimball AB; Kirby J; Lowes MA; Micheletti R; Miller A; Naik HB; Orgill D; Poulin Y
J Am Acad Dermatol; 2019 Jul; 81(1):91-101. PubMed ID: 30872149
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
27. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.
Zouboulis CC; Bechara FG; Fritz K; Goebeler M; Hetzer FH; Just E; Kirsten N; Kokolakis G; Kurzen H; Nikolakis G; Pinter A; Podda M; Rosinski K; Schneider-Burrus S; Taube KM; Volz T; Winkler T; Kristandt A; Presser D; Zouboulis VA
J Dtsch Dermatol Ges; 2024 Jun; 22(6):868-889. PubMed ID: 38770982
[TBL] [Abstract][Full Text] [Related]
28. Boils at Frictional Locations in a Patient with Hidradenitis Suppurativa.
Boer J; Mihajlovic D
Acta Dermatovenerol Croat; 2016 Dec; 24(4):303-304. PubMed ID: 28128084
[TBL] [Abstract][Full Text] [Related]
29. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.
Molinelli E; Brisigotti V; Simonetti O; Sapigni C; D'Agostino GM; Rizzetto G; Giacchetti A; Offidani A
Dermatol Ther; 2022 Jun; 35(6):e15439. PubMed ID: 35278025
[TBL] [Abstract][Full Text] [Related]
31. Management of patients with hidradenitis suppurativa.
Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
[TBL] [Abstract][Full Text] [Related]
32. [Acne inversa (hidradenitis suppurativa)].
Iesalnieks I; Dornseifer U
Chirurg; 2020 Apr; 91(4):293-300. PubMed ID: 31915870
[TBL] [Abstract][Full Text] [Related]
33. British Association of Dermatologists National Clinical Audit on the Management of Hidradenitis Suppurativa in the UK.
Hasan SB; Smith SP; Brain A; Mohd Mustapa MF; Cheung ST; Ingram JR; de Berker DAR
Clin Exp Dermatol; 2021 Aug; 46(6):1023-1027. PubMed ID: 33577133
[TBL] [Abstract][Full Text] [Related]
34. An Update on Medical Treatment Options for Hidradenitis Suppurativa.
Deckers IE; Prens EP
Drugs; 2016 Feb; 76(2):215-29. PubMed ID: 26659474
[TBL] [Abstract][Full Text] [Related]
35. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Yen CF; Huang YH; Chi CC
Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
[TBL] [Abstract][Full Text] [Related]
36. Effective modified conservative tissue preserving protocol to treat stage I axillary hidradenitis suppurativa: a prospective cohort study of 627 patients with five years follow-up.
Shirah BH; Shirah HA
J Dermatolog Treat; 2017 Aug; 28(5):458-463. PubMed ID: 27981857
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
Vekic DA; Frew JW
Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
[No Abstract] [Full Text] [Related]
38. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.
Mendonça CO; Griffiths CE
Br J Dermatol; 2006 May; 154(5):977-8. PubMed ID: 16634904
[TBL] [Abstract][Full Text] [Related]
39. Hidradenitis suppurativa: an update.
Ingram JR
Clin Med (Lond); 2016 Feb; 16(1):70-3. PubMed ID: 26833521
[TBL] [Abstract][Full Text] [Related]
40. [Systemic treatment of moderate/severe hidradenitis suppurativa].
Pinter A; Mrowietz U; Volz T
Hautarzt; 2021 Aug; 72(8):686-691. PubMed ID: 34189590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
